Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Systemic Lupus Erythematosus: HELP
Articles by Francesca Marchiori
Based on 3 articles published since 2010
(Why 3 articles?)
||||

Between 2010 and 2020, F. Marchiori wrote the following 3 articles about Lupus Erythematosus, Systemic.
 
+ Citations + Abstracts
1 Guideline EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. 2017

Andreoli, L / Bertsias, G K / Agmon-Levin, N / Brown, S / Cervera, R / Costedoat-Chalumeau, N / Doria, A / Fischer-Betz, R / Forger, F / Moraes-Fontes, M F / Khamashta, M / King, J / Lojacono, A / Marchiori, F / Meroni, P L / Mosca, M / Motta, M / Ostensen, M / Pamfil, C / Raio, L / Schneider, M / Svenungsson, E / Tektonidou, M / Yavuz, S / Boumpas, D / Tincani, A. ·Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. · Unit of Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy. · Department of Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, Heraklion, Greece. · The Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel. · The Faculty of Medicine, Tel Aviv University, Israel. · Royal National Hospital For Rheumatic Diseases, Bath, UK. · Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Catalonia, Spain. · AP-HP, Hôpital Cochin, Centre de référence maladies auto-immunes et systémiques rares, Paris, France. · Université Paris Descartes-Sorbonne Paris Cité, Paris, France. · Rheumatology Unit, Department of Medicine, University of Padua, Italy. · Policlinic of Rheumatology, Hiller Research Unit, University Clinic Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany. · Department of Rheumatology, Immunology and Allergology, University Hospital of Bern, Bern, Switzerland. · Unidade de Doenças Auto-imunes-Serviço Medicina Interna 7.2, Hospital Curry Cabral/Centro Hospitalar Lisboa Central, NEDAI/SPMI, Lisboa, Portugal. · Lupus Research Unit, The Rayne Institute, St. Thomas Hospital, London, UK. · Department of Rheumatology, Dubai Hospital, Dubai, United Arab Emirates. · EULAR PARE Patient Research Partner, London, UK. · Unit of Obstetrics and Gynaecology, Spedali Civili, Brescia, Italy. · EULAR PARE Patient Research Partner, Rome, Italy. · Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Milan, Italy. · Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. · Neonatology and Neonatal Intensive Care Unit, Spedali Civili, Brescia, Italy. · Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. · Department of Rheumatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania. · Department of Obstetrics and Gynaecology, University Hospital of Bern, Inselspital, Switzerland. · Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. · Rheumatology Unit, Joint Academic Rheumatology Programme, 1st Department of Propaedeutic Internal Medicine Athens, National and Kapodistrian University of Athens, Athens, Greece. · Department of Rheumatology, Istanbul Bilim University, Istanbul Florence Nightingale Hospital, Esentepe-Istanbul, Turkey. · 4th Department of Internal Medicine, 'Attikon' University Hospital, Medical School, University of Athens, Athens, Greece. · Joint Academic Rheumatology Program, National and Kapodestrian University of Athens, Athens, Greece. ·Ann Rheum Dis · Pubmed #27457513.

ABSTRACT: OBJECTIVES: Develop recommendations for women's health issues and family planning in systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). METHODS: Systematic review of evidence followed by modified Delphi method to compile questions, elicit expert opinions and reach consensus. RESULTS: Family planning should be discussed as early as possible after diagnosis. Most women can have successful pregnancies and measures can be taken to reduce the risks of adverse maternal or fetal outcomes. Risk stratification includes disease activity, autoantibody profile, previous vascular and pregnancy morbidity, hypertension and the use of drugs (emphasis on benefits from hydroxychloroquine and antiplatelets/anticoagulants). Hormonal contraception and menopause replacement therapy can be used in patients with stable/inactive disease and low risk of thrombosis. Fertility preservation with gonadotropin-releasing hormone analogues should be considered prior to the use of alkylating agents. Assisted reproduction techniques can be safely used in patients with stable/inactive disease; patients with positive antiphospholipid antibodies/APS should receive anticoagulation and/or low-dose aspirin. Assessment of disease activity, renal function and serological markers is important for diagnosing disease flares and monitoring for obstetrical adverse outcomes. Fetal monitoring includes Doppler ultrasonography and fetal biometry, particularly in the third trimester, to screen for placental insufficiency and small for gestational age fetuses. Screening for gynaecological malignancies is similar to the general population, with increased vigilance for cervical premalignant lesions if exposed to immunosuppressive drugs. Human papillomavirus immunisation can be used in women with stable/inactive disease. CONCLUSIONS: Recommendations for women's health issues in SLE and/or APS were developed using an evidence-based approach followed by expert consensus.

2 Article 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. 2020

Fanouriakis, Antonis / Kostopoulou, Myrto / Cheema, Kim / Anders, Hans-Joachim / Aringer, Martin / Bajema, Ingeborg / Boletis, John / Frangou, Eleni / Houssiau, Frederic A / Hollis, Jane / Karras, Adexandre / Marchiori, Francesca / Marks, Stephen D / Moroni, Gabriella / Mosca, Marta / Parodis, Ioannis / Praga, Manuel / Schneider, Matthias / Smolen, Josef S / Tesar, Vladimir / Trachana, Maria / van Vollenhoven, Ronald F / Voskuyl, Alexandre E / Teng, Y K Onno / van Leew, Bernadette / Bertsias, George / Jayne, David / Boumpas, Dimitrios T. ·Rheumatology and Clinical Immunology Unit, "Attikon" University Hospital, Athens, Greece. · Department of Rheumatology, "Asklepieion" General Hospital, Athens, Greece. · Department of Nephrology, "G. Gennimatas" General Hospital, Athens, Greece. · Department of Medicine, Cambridge University, Cambridge, UK. · Division of Nephrology, Department of Medicine IV, University Hospital LMU Munich, Munich, Germany. · Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus at the TU Dresden, Dresden, Germany. · Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. · Nephrology Department and Renal Transplantation Unit, "Laikon" Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece. · Department of Nephrology, Limassol General Hospital, Limassol, Cyprus. · Cliniques Universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium. · Lupus nurse specialist, Addenbrooke's Hospital, Cambridge, UK. · Department of Nephrology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, France. · Lupus Europe, Rome, Italy. · University College London Great Ormond Street Institute of Child Health, NIHR Great Ormond Street Hospital Biomedical Research Centre, London, UK. · Nephrology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. · Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. · Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Rheumatology, Karolinska University Hospital, Stockholm, Sweden. · Nephrology Department, Research Institute Hospital Universitario 12 de Octubre (i+12), Department of Medicine, Complutense University of Madrid, Madrid, Spain. · Department of Rheumatology & Hiller Research Unit Rheumatology, UKD, Heinrich-Heine University, Duesseldorf, Germany. · Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria. · Department of Nephrology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague, Czech Republic. · Pediatric Immunology and Rheumatology Referral Center, First Pediatric Clinic, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece. · Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands. · Rheumatology and Immunology Center, Amsterdam University Medical Center, Amsterdam, The Netherlands. · Centre of expertise for Lupus-, Vasculitis- and Complement-mediated Systemic autoimmune diseases, Department of Internal Medicine - section Nephrology, Leiden University Medical Center, Leiden, The Netherlands. · Lupus Europe, Essex, UK. · Rheumatology, Clinical Immunology and Allergy, University Hospital of Heraklion, Heraklion, Greece. · Rheumatology and Clinical Immunology Unit, "Attikon" University Hospital, Athens, Greece boumpasd@uoc.gr. · Laboratory of Autoimmunity and Inflammation, Biomedical Research Foundation of the Academy of Athens, Athens, Greece. ·Ann Rheum Dis · Pubmed #32220834.

ABSTRACT: OBJECTIVE: To update the 2012 EULAR/ERA-EDTA recommendations for the management of lupus nephritis (LN). METHODS: Following the EULAR standardised operating procedures, a systematic literature review was performed. Members of a multidisciplinary Task Force voted independently on their level of agreeement with the formed statements. RESULTS: The changes include recommendations for treatment targets, use of glucocorticoids and calcineurin inhibitors (CNIs) and management of end-stage kidney disease (ESKD). The target of therapy is complete response (proteinuria <0.5-0.7 g/24 hours with (near-)normal glomerular filtration rate) by 12 months, but this can be extended in patients with baseline nephrotic-range proteinuria. Hydroxychloroquine is recommended with regular ophthalmological monitoring. In active proliferative LN, initial (induction) treatment with mycophenolate mofetil (MMF 2-3 g/day or mycophenolic acid (MPA) at equivalent dose) or low-dose intravenous cyclophosphamide (CY; 500 mg × 6 biweekly doses), both combined with glucocorticoids (pulses of intravenous methylprednisolone, then oral prednisone 0.3-0.5 mg/kg/day) is recommended. MMF/CNI (especially tacrolimus) combination and high-dose CY are alternatives, for patients with nephrotic-range proteinuria and adverse prognostic factors. Subsequent long-term maintenance treatment with MMF or azathioprine should follow, with no or low-dose (<7.5 mg/day) glucocorticoids. The choice of agent depends on the initial regimen and plans for pregnancy. In non-responding disease, switch of induction regimens or rituximab are recommended. In pure membranous LN with nephrotic-range proteinuria or proteinuria >1 g/24 hours despite renin-angiotensin-aldosterone blockade, MMF in combination with glucocorticoids is preferred. Assessment for kidney and extra-renal disease activity, and management of comorbidities is lifelong with repeat kidney biopsy in cases of incomplete response or nephritic flares. In ESKD, transplantation is the preferred kidney replacement option with immunosuppression guided by transplant protocols and/or extra-renal manifestations. Treatment of LN in children follows the same principles as adult disease. CONCLUSIONS: We have updated the EULAR recommendations for the management of LN to facilitate homogenization of patient care.

3 Article EULAR recommendations for the management of antiphospholipid syndrome in adults. 2019

Tektonidou, Maria G / Andreoli, Laura / Limper, Marteen / Amoura, Zahir / Cervera, Ricard / Costedoat-Chalumeau, Nathalie / Cuadrado, Maria Jose / Dörner, Thomas / Ferrer-Oliveras, Raquel / Hambly, Karen / Khamashta, Munther A / King, Judith / Marchiori, Francesca / Meroni, Pier Luigi / Mosca, Marta / Pengo, Vittorio / Raio, Luigi / Ruiz-Irastorza, Guillermo / Shoenfeld, Yehuda / Stojanovich, Ljudmila / Svenungsson, Elisabet / Wahl, Denis / Tincani, Angela / Ward, Michael M. ·First Department of Propaedeutic Internal Medicine, Joint Rheumatology program, National and Kapodistrian University of Athens, Athens, Greece mtektonidou@gmail.com. · Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy. · Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands. · Sorbonne University, French National Center for SLE and Aps, Service de Medecine Interne 2, InstitutE3M, Pitié Salpétrière, Paris, France. · Autoimmune Diseases, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain. · Centre de référence maladies auto-immunes et systémiques rares de l'île deFrance, Cochin Hospital, Université Paris Descartes-Sorbonne Paris Cité;INSERM U 1153, CRESS, Paris, France. · Rheumatology Department, Clinica Universidad de Navarra, Madrid, Spain. · Department of Med/Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany. · Obstetrics and Gynecology Department and Systemic Diseases Research Unit, Vall ďHebron Research Institute-VHIR, Barcelona, Spain. · School of Sport and Exercise Sciences, University of Kent, Chatham, UK. · Rheumatology Department, Dubai Hospital, Dubai, United Arab Emirates. · EULAR PARE Patient Research Partner, London, UK. · EULAR PARE Patient Research Partner, Rome, Italy. · MaACR, Immunorheumatology Research Laboratory, Istituto Auxologico Italiano, Milan, Italy. · Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy. · Department of Cardiac Thoracic and Vascular Sciences and Public Health, University of Padova, Padua, Italy. · Department of Obstetrics and Gynaecology, University Hospital of Bern, Inselspital, Bern, Switzerland. · Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain. · Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Aviv University, Israel. · Bezhanijska Kosa, Belgrade University, Belgrade, Serbia. · Department of Medicine, Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden. · Vascular Medicine Division and Regional Competence Center for Rare Vascular and Systemic Autoimmune Diseases and Vascular Medicine Division, Nancy University Hospital, INSERM UMR-S 1116 University of Lorraine, Nancy, France. · Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA. ·Ann Rheum Dis · Pubmed #31092409.

ABSTRACT: The objective was to develop evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. Based on evidence from a systematic literature review and expert opinion, overarching principles and recommendations were formulated and voted. High-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS. Risk modification includes screening for and management of cardiovascular and venous thrombosis risk factors, patient education about treatment adherence, and lifestyle counselling. Low-dose aspirin (LDA) is recommended for asymptomatic aPL carriers, patients with systemic lupus erythematosus without prior thrombotic or obstetric APS, and non-pregnant women with a history of obstetric APS only, all with high-risk aPL profiles. Patients with APS and first unprovoked venous thrombosis should receive long-term treatment with vitamin K antagonists (VKA) with a target international normalised ratio (INR) of 2-3. In patients with APS with first arterial thrombosis, treatment with VKA with INR 2-3 or INR 3-4 is recommended, considering the individual's bleeding/thrombosis risk. Rivaroxaban should not be used in patients with APS with triple aPL positivity. For patients with recurrent arterial or venous thrombosis despite adequate treatment, addition of LDA, increase of INR target to 3-4 or switch to low molecular weight heparin may be considered. In women with prior obstetric APS, combination treatment with LDA and prophylactic dosage heparin during pregnancy is recommended. In patients with recurrent pregnancy complications, increase of heparin to therapeutic dose, addition of hydroxychloroquine or addition of low-dose prednisolone in the first trimester may be considered. These recommendations aim to guide treatment in adults with APS. High-quality evidence is limited, indicating a need for more research.